Mylan Gears Up To Launch US Advair Rival This Month
Mylan has revealed that its Wixela Inhub US rival to GSK’s Advair Diskus will be on the market by the end of February, acting quickly after their recent FDA approval.
You may also be interested in...
A six-year Mylan employee, Dayakar Mallu, is facing up to six years in jail after pleading guilty to insider trading and tax offence charges.
Mylan has launched its Wixela Inhub rival to GSK’s Advair Diskus at a 70% discount to the brand price.
The latest drug development news and highlights from our US FDA Performance Tracker.